scholarly journals Changes in the quick mild cognitive impairment test over time: A normative study in an adult sample in Taiwan

2021 ◽  
Author(s):  
Chen-Tse Lee ◽  
Kuang-Cheng Chan ◽  
Fon-Yih Tsuang ◽  
Chih-Peng Lin ◽  
Chun-Yu Wu
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Normative Study ◽  
Adult Sample ◽  
Over Time

Potenziamento della capacitÀ mentale? Dalla medicalizzazione della cognizione alla farmacologizzazione delle routine mental life

2012 ◽  
pp. 145-159
Author(s):  
Catherine Coveney ◽  
Jonathan Gabe ◽  
Simon Williams
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Research Agenda ◽  
Cognitive Enhancement ◽  
Early Stage ◽  
Mental Life ◽  
Medical Authority ◽  
Pharmaceutical Cognitive Enhancement ◽  
Promise Problems ◽  
Over Time

Sociological engagement with debates around the promise, problems and prospects of pharmaceutical cognitive enhancment is still at an early stage. In this paper we attempt to explore how the prospect of cognitive enhancement can be understood using existing sociological concepts of medicalisation, biomedicalisation and pharmaceuticalisation. Drawing on two case studies, that of Mild Cognitive Impairment (MCI) and the use of modafinil to enhance alertness, we discuss the idea of enhancement medicine and the use of cognitive enhancers outside of medical authority. We suggest that whilst all three of the above concepts shed important light on these developments, overlapping and converging as they do in various ways, pharmaceuticalisation provides a more precise sociological term of reference. We end with some suggestions for a research agenda for tracing and tracking trends in pharmaceutical cognitive enhancement over time.

The Transition of Mild Cognitive Impairment Over Time: An AV45- and FDG-PET Study of Reversion and Conversion Phenomena

2021 ◽  
Vol 18 ◽  
Author(s):  
Amir Ashraf-Ganjouei ◽  
Kamyar Moradi ◽  
Shahriar Faghani ◽  
AmirHussein Abdolalizadeh ◽  
Mohammadreza Khomeijani-Farahani ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Glucose Metabolism ◽  
Pet Imaging ◽  
Fdg Pet ◽  
Amyloid Β ◽  
Positron Emission ◽  
One Year ◽  
T Tau ◽  
Over Time

Background: Mild cognitive impairment (MCI) is a state between normal cognition and dementia. However, MCI diagnosis does not necessarily guarantee the progression to dementia. Since no previous study investigated brain positron emission tomography (PET) imaging of MCI-- to-normal reversion, we provided PET imaging of MCI-to-normal reversion using the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Methods: We applied comprehensive neuropsychological criteria (NP criteria), consisting of mem- ory, language, and attention/executive function domains, to include patients with a baseline diagno- sis of MCI (n=613). According to the criteria, the year 1 status of the patients was categorized into three groups (reversion: n=105, stable MCI: n=422, conversion: n=86). Demographic, neuropsycho- logical, genetic, CSF, and cognition biomarker variables were compared between the groups. Addi- tionally, after adjustment for confounding variables, the deposition pattern of amyloid-β and cere- bral glucose metabolism were compared between three groups via AV45- and FDG-PET modali- ties, respectively. Results: MCI reversion rate was 17.1% during one year of follow-up. The reversion group had the lowest frequency of APOE ε4+ subjects, the highest CSF level of amyloid-β, and the lowest CSF levels of t-tau and p-tau. Neuropsychological assessments were also suggestive of better cognitive performance in the reversion group. Patients with reversion to normal state had higher glucose metabolism in bilateral angular and left middle/inferior temporal gyri, when compared to those with stable MCI state. Meanwhile, lower amyloid-β deposition at baseline was observed in the fron- tal and parietal regions of the reverted subjects. On the other hand, the conversion group showed lower cerebral glucose metabolism in bilateral angular and bilateral middle/inferior temporal gyri compared to the stable MCI group, whereas the amyloid-β accumulation was similar between the groups. Conclusions: This longitudinal study provides novel insight regarding the application of PET imag- ing in predicting MCI transition over time.

scholarly journals Progression of mild cognitive impairment to dementia: a challenge to current thinking

2006 ◽  
Vol 189 (5) ◽  
pp. 399-404 ◽  
Author(s):  
Anja Busse ◽  
Matthias C. Angermeyer ◽  
Steffi G. Riedel-Heller
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Community Sample ◽  
Neuropsychological Testing ◽  
Time Dependent ◽  
Current Thinking ◽  
Conversion Rates ◽  
Over Time ◽  
Long Term Studies

BackgroundStudies of conversion from mild cognitive impairment to dementia suggest a linear progression over time. Conversion rates during lifetime may extend to 80–90%.AimsThis study examines the time-dependent evolution from mild cognitive impairment to dementia. Current assumptions regarding yearly and lifetime conversion rates are challenged.MethodA community sample of 1045 dementia-free individuals aged 75 years and over was examined by neuropsychological testing based on 6 years of observation.ResultsApproximately 60–65% of people with mild cognitive impairment develop clinical dementia during their life. Progression from mild cognitive impairment to dementia appears to be time dependent, occurring primarily within the initial 18 months.ConclusionsFurther long-term studies are needed to examine the time-dependent evolution from mild cognitive impairment to dementia and to establish age-specific conversion rates during lifetime.

Boosting brainpower? From the medicalisation of cognition to the pharmaceuticalisation of routine mental life

2013 ◽  
pp. 151-165
Author(s):  
Catherine Coveney ◽  
Jonathan Gabe ◽  
Simon Williams
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Research Agenda ◽  
Cognitive Enhancement ◽  
Early Stage ◽  
Mental Life ◽  
Medical Authority ◽  
Pharmaceutical Cognitive Enhancement ◽  
Promise Problems ◽  
Over Time

Sociological engagement with debates around the promise, problems and prospects of pharmaceutical cognitive enhancment is still at an early stage. In this paper we attempt to explore how the prospect of cognitive enhancement can be understood using existing sociological concepts of medicalisation, biomedicalisation and pharmaceuticalisation. Drawing on two case studies, that of Mild Cognitive Impairment (MCI) and the use of modafinil to enhance alertness, we discuss the idea of enhancement medicine and the use of cognitive enhancers outside of medical authority. We suggest that whilst all three of the above concepts shed important light on these developments, overlapping and converging as they do in various ways, pharmaceuticalisation provides a more precise sociological term of reference. We end with some suggestions for a research agenda for tracing and tracking trends in pharmaceutical cognitive enhancement over time.

scholarly journals Obstructive Sleep Apnea is Associated with Longitudinal Increases in Amyloid Burden in Elderly Mild Cognitive Impairment Individuals

2019 ◽  
Vol 15 (4) ◽  
pp. 71-77 ◽  
Author(s):  
Megan Hogan ◽  
Amanda Shim ◽  
Ogie Queen Umasabor-Bubu ◽  
Mukhtar Fahad ◽  
Omonigho Michael Bubu
Keyword(s):  
Obstructive Sleep Apnea ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Sleep Apnea ◽  
Rate Of Change ◽  
Amyloid Pet ◽  
Amyloid Burden ◽  
Obstructive Sleep ◽  
History Of ◽  
Over Time

Cross sectional analysis has shown an association between Obstructive Sleep Apnea (OSA) severity and Aβ burden using amyloid-PET among Mild Cognitive Impairment (MCI) patients. However, whether OSA accelerates longitudinal increases in amyloid beta (Aβ) burden in MCI patients is presently unclear. Study participants included a total of 798 subjects with a diagnosis of MCI and were a subset of the ADNI cohort (adni.loni.usc.edu). OSA was self-reported and participants were labeled either as OSA+ or OSA−. Aβ burden was determined by florbetapir SUVRs. To test whether OSA is associated with the rate of change in Aβ data longitudinally, multilevel mixed effects linear regression was used to fit the models with randomly varying intercepts and slopes allowing dependence on OSA status. The final model was adjusted for age, sex, body mass index, education, CPAP use status, history of respiratory disease, hypertension, diabetes, and history of cardiovascular disease. A significant variation in the change (slope) in Aβ volumes over time was seen (p<.0001). The covariance between the baseline Aβ level and Aβ volume change over time indicated that OSA subjects experienced greater mean change differences in brain Aβ volumes over time (p < .0001). The rate of change in Aβ deposition also varied significantly across OSA groups over the follow-up period. Obstructive Sleep Apnea possibly facilitates longitudinal increases in amyloid burden in elderly Mild Cognitive Impairment individuals. Further research examining mechanisms underlying effects of OSA on the longitudinal increases in Aβ burden is needed.

Sign in / Sign up

Export Citation Format

Share Document